A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations

Trial Profile

A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2016 According to Clinicaltrials.gov record Dosage of Ponatinib has been changed from 45 mg PO daily to 35 mg PO daily.
    • 16 Mar 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 08 Sep 2014 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top